Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravesical apaziquone vs placebo in low–intermediate risk non‑muscle invasive bladder cancer
2011-003517-42Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Oct 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-muscle-invasive bladder cancer (NMIBC) comparing Apaziquone with Placebo (2 arms). Primary endpoint: Time to first confirmed bladder cancer recurrence. Started Oct 2011; status: completed.
02
Drugs
apaziquone
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2011-003517-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003517-42.